Roivant Sciences Ltd (ROIV)
11.22
-0.18
(-1.62%)
USD |
NASDAQ |
May 17, 16:00
11.22
0.00 (0.00%)
After-Hours: 20:00
Roivant Sciences Total Assets (Quarterly): 7.313B for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.313B |
| September 30, 2023 | 2.066B |
| June 30, 2023 | 2.137B |
| March 31, 2023 | 2.390B |
| December 31, 2022 | 2.203B |
| September 30, 2022 | 2.216B |
| Date | Value |
|---|---|
| June 30, 2022 | 2.600B |
| March 31, 2022 | 2.585B |
| December 31, 2021 | 2.799B |
| September 30, 2021 | 3.103B |
| June 30, 2021 | 2.455B |
| March 31, 2021 | 2.590B |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
2.066B
Minimum
Sep 2023
7.313B
Maximum
Dec 2023
2.871B
Average
2.520B
Median
Total Assets (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 258.01M |
| Biodexa Pharmaceuticals Plc | 13.43M |
| Verona Pharma PLC | 289.91M |
| NuCana PLC | 35.43M |
| Autolus Therapeutics PLC | 375.38M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 728.10M |
| Shareholders Equity (Quarterly) | 6.090B |
| Debt to Equity Ratio | 0.0737 |
| Current Ratio | 27.79 |
| Net Debt Paydown Yield | -0.08% |